



PCT/EP 03 / 10261 10/527481



#2

EP03/10261

INVESTOR IN PEOPLE

REC'D 10 OCT 2003

WIPO

PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *AmBrenner*

Dated 6 August 2003

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

An Executive Agency of the Department

Best Available Copy



The
Patent
Office

13SEP02 E747835-1 002029
P01/7700 0 00-02/21157-1

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

LK/PMS/P33107

2. Patent application number

(The Patent Office will fill in his part)

0221157.1

12 SEP 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

United Kingdom

473587003

4. Title of the invention

Novel Treatment

5. Name of your agent (*if you have one*)

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

Patents ADP number (*if you know it*)

Corporate Intellectual Property

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

7960982003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (*if you know it*) the or each application number

Country Priority application number Date of filing
(*if you know it*) (*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application Date of filing
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer yes if:*

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is named as an applicant, or
- c) any named applicant is a corporate body

See note (d)

Patents Form 1/77

9. ☒ the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	7
Claim(s)	0
Abstract	0
Drawings	0

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

We request the grant of a patent on the basis of this application

Signature

K Rutter

Date 12-Sep-02

12. Name and daytime telephone number of person to contact in the United Kingdom

K Rutter 01279 644396

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

NOVEL TREATMENT

This invention relates to a novel treatment and in particular to a method for the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith.

Vanilloids are a class of natural and synthetic compounds that are characterised by the presence of a vanillyl (4-hydroxy 3-methoxybenzyl) group or a functionally equivalent group. Vanilloid Receptor (VR-1), whose function is modulated by such compounds, has been widely studied and is extensively reviewed by Szallasi and Blumberg (The American Society for Pharmacology and Experimental Therapeutics, 1999, Vol. 51, No. 2.).

A wide variety of Vanilloid compounds of different structures are known in the art, for example those disclosed in European Patent Application Numbers, EP 0 347 000 and EP 0 401 903, UK Patent Application Number GB 2226313 and International Patent Application, Publication Number WO 92/09285. Particularly notable examples of vanilloid compounds or vanilloid receptor modulators are capsaicin or trans 8-methyl-N-vanillyl-6-nonenamide which is isolated from the pepper plant, capsazepine (*Tetrahedron*, **53**, 1997, 4791) and olvanil or - N-(4-hydroxy-3-methoxybenzyl)oleamide (*J. Med. Chem.*, **36**, 1993, 2595).

US Patent Numbers, US 3,424,760 and US 3,424,761 both describe a series of 3-Ureidopyrrolidines that are said to exhibit analgesic, central nervous system, and psychopharmacologic activities.

International Patent Application, Publication Number WO 01/021577 discloses the preparation of a series of N-tetrahydronaphthalenyl derivatives, having biological activity as melanin-concentrating hormone antagonists.

International Patent Application, Publication Number WO 02/08221 discloses diaryl piperazine and related compounds which bind with high selectivity and high affinity to vanilloid receptors, especially Type I Vanilloid receptors, also known as capsaicin or VR-1 receptors. The compounds are said to be useful in the treatment of chronic and acute pain conditions, itch and urinary incontinence. International

Patent Application, Publication Numbers WO 02/16317, WO 02/16318 and WO 02/16319 suggest that compounds having a high affinity for the vanilloid-receptor are useful for treating stomach-duodenal ulcers.

It is now surprisingly indicated that compounds having activity as Vanilloid receptor antagonists have activity in the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith.

Accordingly, the invention provides a method for the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith, in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a Vanilloid receptor antagonist.

Suitably, the invention provides a method for the treatment and/or prophylaxis of pelvic pain.

Suitably, the invention provides a method for the treatment and/or prophylaxis of renal colic or pain associated therewith.

Suitably, the invention provides a method for the treatment and/or prophylaxis of biliary colic or pain associated therewith.

Suitably, the invention provides a method for the treatment and/or prophylaxis of functional dyspepsia or pain associated therewith, such as, heartburn.

Suitably, the invention provides a method for the treatment and/or prophylaxis of Barrett's metaplasia or pain associated therewith.

Suitably, the invention provides a method for the treatment and/or prophylaxis of dysphagia or pain associated therewith.

Suitably, the Vanilloid receptor antagonist is an antagonist of the Vanilloid receptor-1.

Suitable Vanilloid receptor antagonists for use in accordance with the present invention include those disclosed in European Patent numbers EP 0 347 000 and EP 0 401 903, UK Patent Application Number GB 2226313, International Patent Applications, Publication Numbers WO 92/09285, WO 01/021577, WO

02/08221, WO 02/16317, WO 02/16318 and WO 02/16319 and US Patent Numbers, US 3,424,760 and US 3,424,761

5 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

10 Certain Vanilloid receptor antagonists may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof. Where a Vannilod receptor antagonist contains a chiral carbon, and hence exists in one or more stereoisomeric forms or where one or more geometric isomers exist, it will be appreciated that the method of the present invention encompasses all of the said forms of the Vanilloid receptor antagonists whether as individual isomers or as mixtures of isomers, including racemates.

15 When used herein the term 'Vanilloid receptor antagonist' relates to an antagonist, such as a small molecular weight antagonist, of the Vanilloid receptor. It will be appreciated that the term also embraces suitable pharmaceutically acceptable derivatives thereof.

20 Vanilloid receptor antagonist activity may be assessed by use of the methodologies disclosed in the above-mentioned patent applications, such as, WO 02/08221 and WO 02/16317 and copending International Patent Application Number PCT/EP02/04802.

Suitable pharmaceutically acceptable derivatives of a Vanilloid receptor antagonist are, for example, salts and solvates.

25 Suitable pharmaceutically acceptable derivatives of any particular Vanilloid receptor antagonist include those disclosed in the above-mentioned publications.

Suitable pharmaceutically acceptable salts include salts derived from appropriate acids, such as acid addition salts, or bases.

30 Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline

earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.

Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulfate, nitrate, phosphate, borate, hydrochloride and

hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulfonate, α -keto glutarate and α -glycerophosphate, especially the maleate salt.

The Vanilloid receptor antagonists, referred to herein are conveniently prepared according to the methods disclosed in the above mentioned patent publications in which they are disclosed.

The salts and/or solvates of the Vanilloid receptor antagonists may be prepared and isolated according to conventional procedures for example those disclosed in the above mentioned patent publications.

The present invention also provides a Vanilloid receptor antagonist or a pharmaceutically acceptable derivative thereof, for use in the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith.

The present invention also provides a Vanilloid receptor antagonist or a pharmaceutically acceptable derivative thereof, for use in the manufacture of a medicament for the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith.

In the above-mentioned method the Vanilloid receptor antagonist, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

In the treatment of the invention, the Vanilloid receptor antagonist mentioned herein is formulated and administered in accordance with the methods disclosed in the above mentioned patent applications and patents.

Accordingly, the present invention also provides a pharmaceutical
5 composition for the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith, which composition comprises a Vanilloid antagonist, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier therefor.

10 As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

15 Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.

Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as
20 powders presented in sachets, may also be used.

In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.

Typical carriers include, for example, microcrystalline cellulose, starch,
25 sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.

Suitable dosages of the Vanilloid receptor antagonist include the known doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack
30 Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical

Press) (for example see the 31st Edition page 341 and pages cited therein) or the
~~above mentioned publications or doses which can be determined by standard~~
procedures.

The solid oral compositions may be prepared by conventional methods of
5 blending, filling or tableting. Repeated blending operations may be used to
distribute the active agent throughout those compositions employing large quantities
of fillers. Such operations are of course conventional in the art. The tablets may be
coated according to methods well known in normal pharmaceutical practice, in
particular with an enteric coating.

10 Oral liquid preparations may be in the form of, for example, emulsions,
syrops, or elixirs, or may be presented as a dry product for reconstitution with water
or other suitable vehicle before use. Such liquid preparations may contain
conventional additives such as suspending agents, for example sorbitol, syrup,
methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium
15 stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin,
sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible
oils), for example almond oil, fractionated coconut oil, oily esters such as esters of
glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or
propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or
20 colouring agents.

For parenteral administration, fluid unit dosage forms are prepared utilizing
the compound and a sterile vehicle, and, depending on the concentration used, can
be either suspended or dissolved in the vehicle. In preparing solutions the
compound can be dissolved in water for injection and filter sterilized before filling
25 into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a
local anaesthetic, a preservative and buffering agents can be dissolved in the
vehicle. To enhance the stability, the composition can be frozen after filling into the
vial and the water removed under vacuum. Parenteral suspensions are prepared in
substantially the same manner, except that the compound is suspended in the
30 vehicle instead of being dissolved, and sterilization cannot be accomplished by

filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

Compositions may contain from 0.1% to 99% by weight, preferably from
5 10-60% by weight, of the active material, depending upon the method of administration.

Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

The compositions are formulated according to conventional methods, such as
10 those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books).

No adverse toxicological effects are expected for the compositions or
15 methods of the invention in the above mentioned dosage ranges.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.